Stryker Corporation (SYK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Stryker's revenue growth has moderated to 7.6% year over year in 2026Q3 from 11.4% in 2025Q4, while gross margin swung between 61.3% and 68.3% over the ten reported quarters, suggesting pricing and operating leverage remain inconsistent.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has moderated to 7.6% in 2026Q3 while operating margin compressed to 15.9% from 27.3% in 2025Q4, indicating that operating income has not scaled consistently with gross profit.
Stryker Corporation has a wide moat, indicating strong competitive advantages and sustainable profitability in the medical devices sector.
The company benefits from consistent demand for medical procedures, supporting stable revenue growth.
Stryker's continued advancements in medical devices and robotics position it as a leader in healthcare technology.
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $3.52-0.8% vs $3.55 | $6.5B-1.5% vs $6.6B |
Q3 2026 Jul 30, 2026 | $3.69+5.7% vs $3.49 | $6.6B+0.1% vs $6.6B |
Q2 2026 Apr 30, 2026 | $2.60-12.8% vs $2.98 | $6.0B-5.0% vs $6.3B |
Q1 2026 Jan 29, 2026 | $4.47+1.6% vs $4.40 | $7.2B+0.7% vs $7.1B |
Stryker Corporation (SYK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Investors looking for stocks in the Medical - Products sector might want to consider either GE HealthCare Technologies (GEHC) or Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?

Portage, MI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Stryker announces intention to nominate Jim Davis to board of directors Stryker (NYSE: SYK) announced that its board of directors has nominated Jim Davis for election to the company's board, effective Jan. 1, 2027. Jim serves as Chairman, CEO and President of Quest Diagnostics.
Commonwealth Equity Services LLC cut its position in shares of Stryker Corporation (NYSE: SYK) by 5.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,804 shares of the medical technology company's stock after selling 6,085 shares during the
Benchmark SYK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Stryker Corporation (SYK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $317.54 | $121.73B | 33.72 | 11.16% | 13.78% | 15.61% | 1.06% | |
| $102.09 | $19.75B | 25.46 | 7.2% | 8.96% | 6.05% | 0.94% | |
| $43.03 | $63.96B | 17.90 | 19.87% | 16.56% | 13.74% | — | |
| $105.43 | $60.71B | 59.63 | 11.55% | 15.3% | 9.65% | — | |
| $215.42 | $59.36B | 51.61 | -10.91% | 5.66% | 3.67% | 1.93% | |
| $102.32 | $131.37B | 25.14 | 8.43% | 13.93% | 10.51% | 2.76% |
Stryker Corporation (SYK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Stryker Corporation (SYK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 6, 2026·SEC
Jul 30, 2026·SEC
Get notified when SYK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Stryker Corporation (SYK) stock FAQ — growth, dividends, profitability & financials explained
Stryker Corporation (SYK) reported $26.30B in revenue over the trailing twelve months. Revenue was $25.12B in fiscal year 2025. That is 2660% more than the $910.1M of fiscal year 1996.
Stryker Corporation (SYK) grew revenue by 7.9% over the trailing twelve months, compared with the twelve months before.
Yes. Stryker Corporation (SYK) earned $3.62B in net income over the trailing twelve months (a 13.8% net margin).
Yes. Stryker Corporation (SYK) pays a dividend that yields 1.06% at the current price, a moderate yield.
Stryker Corporation (SYK) had a return on equity (ROE) of 15.6% over the trailing twelve months. That is above the market's typical 10-15%.
Stryker Corporation (SYK) generated $4.57B in free cash flow over the trailing twelve months.